References

Aflaki, E., B.K. Stubblefield, R.P. McGlinchey, B. McMahon, D.S. Ory and E. Sidransky, 2020. A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson’s disease. Neurobiol. Dis., Vol. 134, 10.1016/j.nbd.2019.104647

Aharon-Peretz, J., H. Rosenbaum and R. Gershoni-Baruch, 2004. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. New Engl. J. Med., 351: 1972-1977.
CrossRef  |  Direct Link  |  

Anders, C., O. Niewoehner, A. Duerst and M. Jinek, 2014. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature, 513: 569-573.
CrossRef  |  Direct Link  |  

Arends, M., L. van Dussen, M. Biegstraaten and C.E. Hollak, 2013. Malignancies and monoclonal gammopathy in G aucher disease; a systematic review of the literature. Br. J. Haematol., 161: 832-842.
CrossRef  |  Direct Link  |  

Armstrong, L.C., T. Komiya, B.E. Bergman, K. Mihara and P. Bornstein, 1997. Metaxin is a component of a preprotein import complex in the outer membrane of the mammalian mitochondrion. J. Biol. Chem., 272: 6510-6518.
CrossRef  |  Direct Link  |  

Ayto, R. and D.A. Hughes, 2013. Gaucher disease and myeloma. Crit. Rev.™ Oncogenesis, 18: 247-268.
CrossRef  |  Direct Link  |  

Barak, V., M. Acker, B. Nisman, I. Kalickman, A. Abrahamov, A. Zimran and S. Yatziv, 1999. Cytokines in Gaucher’s disease. Eur. Cytokine Network, 10: 205-210.
Direct Link  |  

Barrangou, R., P. Boyaval, S. Moineau, D.A. Romero and P. Horvath, 2007. CRISPR provides acquired resistance against viruses in prokaryotes. Sci., 315: 1709-1712.
CrossRef  |  

Barth, B.M., S.S. Shanmugavelandy, D.M. Tacelosky, M. Kester, S.A. Morad and M.C. Cabot, 2013. Gaucher’s disease and cancer: A sphingolipid perspective. Crit. Rev.™ Oncogenesis, 18: 221-234.
CrossRef  |  Direct Link  |  

Batta, G., L. Soltesz, T. Kovacs, T. Bozo and Z. Meszar et al., 2018. Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease. Sci. Rep., 8: 1-13.
CrossRef  |  Direct Link  |  

Beals, J.K., 2008. ASHG 2008: Gaucher disease mutation carriers at higher risk for parkinson’s disease. Medscape Medical News, USA.

Belfort, M. and R.P. Bonocora, 2014. Homing endonucleases: From genetic anomalies to programmable genomic clippers. Methods Mol. Biol., 1123: 1-26.
CrossRef  |  Direct Link  |  

Beutler, E. and G.A. Grabowski, 2001. Gaucher Disease: The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill, New York, USA., pp: 3635-3668.

Beutler, E., 1991. Gaucher’s disease. New Engl. J. Med., 325: 1354-1360.
CrossRef  |  Direct Link  |  

Brady, R.O., J.N. Kanfer and D. Shapiro, 1965. Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem. Biophys. Res. Commun., 18: 221-225.
CrossRef  |  Direct Link  |  

Braunstein, H., G. Maor, G. Chicco, M. Filocamo, A. Zimran and M. Horowitz, 2018. UPR activation and CHOP mediated induction of GBA1 transcription in Gaucher disease. Blood Cells Mol. Dis., 68: 21-29.
CrossRef  |  Direct Link  |  

Christensen, C.L. and F.Y. Choy, 2017. A prospective treatment option for lysosomal storage diseases: CRISPR/Cas9 gene editing technology for mutation correction in induced pluripotent stem cells. Diseases, Vol. 5, No. 1. 10.3390/diseases5010006

Dahl, N., M. Lagerstrom, A. Erikson and U. Pettersson, 1990. Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am. J. Hum. Genet., 47: 275-278.

Dandana, A., S.B. Khelifa, H. Chahed, A. Miled and S. Ferchichi, 2016. Gaucher disease: Clinical, biological and therapeutic aspects. Pathobiology, 83: 13-23.
CrossRef  |  Direct Link  |  

Deegan, P.B. and T.M. Cox, 2012. Imiglucerase in the treatment of Gaucher disease: A history and perspective. Drug Design Dev. Ther., 6: 81-106.
CrossRef  |  Direct Link  |  

Diaz, G.A., B.D. Gelb, N. Risch, T.G. Nygaard and A. Frisch et al., 2000. Gaucher disease: The origins of the Ashkenazi Jewish N370S and 84GG acid β-glucosidase mutations. Am. J. Hum. Genet., 66: 1821-1832.
CrossRef  |  Direct Link  |  

Doss, M.X. and A. Sachinidis, 2019. Current challenges of iPSC-based disease modeling and therapeutic implications. Cells, Vol. 8, No. 5. 10.3390/cells8050403

Dossi, E., F. Vasile and N. Rouach, 2018. Human astrocytes in the diseased brain. Brain Res. Bull., 136: 139-156.
CrossRef  |  Direct Link  |  

Dow, L.E., J. Fisher, K.P. O’rourke, A. Muley and E.R. Kastenhuber et al., 2015. Inducible in vivo genome editing with CRISPR-Cas9. Nature Biotechnol., 33: 390-394.
CrossRef  |  Direct Link  |  

Dreborg, S., A. Erikson and B. Hagberg, 1980. Gaucher disease-norrbottnian type. Eur. J. Pediatr., 133: 107-118.
CrossRef  |  Direct Link  |  

Drews, K., M.P. Calgi, W.C. Harrison, C.M. Drews and P. Costa-Pinheiro et al., 2019. Glucosylceramidase maintains influenza virus infection by regulating endocytosis. J. Virol., Vol. 93, 10.1128/JVI.00017-19

Farfel-Becker, T., E. Vitner, H. Dekel, N. Leshem, I.B. Enquist, S. Karlsson and A.H. Futerman, 2009. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum. Mol. Genet., 18: 1482-1488.
CrossRef  |  Direct Link  |  

Gaj, T., C.A. Gersbach and C.F. Barbas III, 2013. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol., 31: 397-405.
CrossRef  |  Direct Link  |  

Gasiunas, G., R. Barrangou, P. Horvath and V. Siksnys, 2012. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci., 109: E2579-E2586.
CrossRef  |  Direct Link  |  

Gegg, M.E. and A.H. Schapira, 2018. The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J., 285: 3591-3603.
CrossRef  |  Direct Link  |  

Goker-Alpan, O., K.S. Hruska, E. Orvisky, P.S. Kishnani, B.K. Stubblefield, R. Schiffmann and E. Sidransky, 2005. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J. Med. Genet., 42: e37-e37.
CrossRef  |  Direct Link  |  

Grabowski, G.A., 2008. Phenotype, diagnosis and treatment of Gaucher’s disease. Lancet, 372: 1263-1271.
CrossRef  |  Direct Link  |  

Grabowski, G.A., 2012. Gaucher disease and other storage disorders. Hematol. Am. Soc. Hematol. Educ. Program, 1: 13-18.
Direct Link  |  

Guan, Y., Y. Ma, Q. Li, Z. Sun and L. Ma et a., 2016. CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol. Med., 8: 477-488.
CrossRef  |  Direct Link  |  

Hein, L.K., P.J. Meikle, J.J. Hopwood and M. Fuller, 2007. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol. Genet. Metab., 92: 336-345.
CrossRef  |  Direct Link  |  

Hoban, M.D., D. Lumaquin, C.Y. Kuo, Z. Romero and J. Long et al., 2016. CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol. Therapy, 24: 1561-1569.
CrossRef  |  Direct Link  |  

Hockemeyer, D. and R. Jaenisch, 2016. Induced pluripotent stem cells meet genome editing. Cell Stem Cell, 18: 573-586.
CrossRef  |  Direct Link  |  

Hong, Y.B., E.Y. Kim and S.C. Jung, 2006. Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse. J. Korean Med. Sci., 21: 733-738.

Hruska, K.S., M.E. LaMarca, C.R. Scott and E. Sidransky, 2008. Gaucher disease: Mutation and polymorphism spectrum in the Glucocerebrosidase Gene (GBA). Hum. Mutat., 29: 567-583.
CrossRef  |  Direct Link  |  

Isalan, M., 2012. Zinc-finger nucleases: How to play two good hands. Nature Methods, 9: 32-34.
CrossRef  |  Direct Link  |  

James, W.D., T.G. Berger, D.M. Elston and R.B. Odom, 2006. Andrews’ Diseases of the Skin: Clinical Dermatology. 10th Edn., Saunders Elsevier, New York, ISBN-10: 0721629210, pp: 961.

Jinek, M., K. Chylinski, I. Fonfara, M. Hauer, J.A. Doudna and E. Charpentier, 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337: 816-821.
CrossRef  |  Direct Link  |  

Linari, S. and G. Castaman, 2015. Clinical manifestations and management of Gaucher disease. Clin. Cases Mineral Bone Metab., 12: 157-164.

Long, C., J.R. McAnally, J.M. Shelton, A.A. Mireault, R. Bassel-Duby and E.N. Olson, 2014. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science, 345: 1184-1188.
CrossRef  |  Direct Link  |  

Long, G.L., S. Winfield, K.W. Adolph, E.I. Ginns and P. Bornstein, 1996. Structure and organization of the human metaxin gene (MTX) and pseudogene. Genomics, 33: 177-184.
CrossRef  |  Direct Link  |  

Maor, G., S. Rencus-Lazar, M. Filocamo, H. Steller, D. Segal and M. Horowitz, 2013. Unfolded protein response in Gaucher disease: From human to drosophila. Orphanet J. Rare Dis., 8: 1-14.
CrossRef  |  Direct Link  |  

Martinez-Arias, R., F. Calafell, E. Mateu, D. Comas, A. Andres and J. Bertranpetit, 2001. Sequence variability of a human pseudogene. Genome Res., 11: 1071-1085.
CrossRef  |  Direct Link  |  

Michelakakis, H., C. Spanou, A. Kondyli, E. Dimitriou and S. Van Weely et al., 1996. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis., 1317: 219-222.
CrossRef  |  Direct Link  |  

Migdalska‐Richards, A. and A.H. Schapira, 2016. The relationship between glucocerebrosidase mutations and Parkinson disease. J. Neurochem., 139: 77-90.
CrossRef  |  Direct Link  |  

Mistry, P.K., G. Lopez, R. Schiffmann, N.W. Barton, N.J. Weinreb and E. Sidransky, 2017. Gaucher disease: Progress and ongoing challenges. Mol. Genet. Metab., 120: 8-21.
CrossRef  |  Direct Link  |  

Moore, J.K. and J.E. Haber, 1996. Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol. Cellular Biol., 16: 2164-2173.
CrossRef  |  Direct Link  |  

Mu, T.W., D.S.T. Ong, Y.J. Wang, W.E. Balch, J.R. Yates III, L. Segatori and J.W. Kelly, 2008. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell, 134: 769-781.
CrossRef  |  Direct Link  |  

Nilsson, O. and L. Svennerholm, 1982. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J. Neurochem., 39: 709-718.
CrossRef  |  Direct Link  |  

Pastores, G.M., 1997. Gaucher’s disease: Pathological features. Bailliere’s Clin. Haematol., 10: 739-749.

Pavan, E., M. Ormazabal, P. Peruzzo, E. Vaena, P. Rozenfeld and A. Dardis, 2020. CRISPR/Cas9 editing for gaucher disease modelling. Int. J. Mol. Sci., Vol. 21, 10.3390/ijms21093268

Phatnani, H. and T. Maniatis, 2015. Astrocytes in neurodegenerative disease. Cold Spring Harbor Perspectives Biol., Vol. 7, No. 6. 10.1101/cshperspect.a020628

Ron, I. and M. Horowitz, 2005. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet., 14: 2387-2398.
CrossRef  |  Direct Link  |  

Santos, R. and O. Amaral, 2019. Advances in sphingolipidoses: CRISPR-Cas9 editing as an option for modelling and therapy. Int. J. Mol. Sci., Vol. 20, 10.3390/ijms20235897

Sapranauskas, R., G. Gasiunas, C. Fremaux, R. Barrangou, P. Horvath and V. Siksnys, 2011. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res., 39: 9275-9282.
CrossRef  |  Direct Link  |  

Sarkar, S., E.B. Dammer, E. Malovic, A.L. Olsen and S.A. Raza et al., 2020. Molecular signatures of neuroinflammation induced by α synuclein aggregates in microglial cells. Frontiers Immunol., Vol. 11,

Schwank, G., B.K. Koo, V. Sasselli, J.F. Dekkers and I. Heo et al., 2013. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 13: 653-658.
CrossRef  |  Direct Link  |  

Seeman, N.C., J.M. Rosenberg and A. Rich, 1976. Sequence-specific recognition of double helical nucleic acids by proteins. Proc. National Acad. Sci., 73: 804-808.
CrossRef  |  Direct Link  |  

Shemesh, E., L. Deroma, B. Bembi, P. Deegan, C. Hollak, N.J. Weinreb and T.M. Cox, 2015. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Systematic Rev., Vol. 3,

Sidransky, E., 2012. Gaucher disease: Insights from a rare mendelian disorder. Discovery Med., 14: 273-281.

Simons, K. and J. Gruenberg, 2000. Jamming the endosomal system: Lipid rafts and lysosomal storage diseases. Trends Cell Biol., 10: 459-462.
CrossRef  |  Direct Link  |  

Sung, K. and M. Jimenez-Sanchez, 2020. Autophagy in astrocytes and its implications in neurodegeneration. J. Mol. Biol., 432: 2605-2621.
CrossRef  |  Direct Link  |  

Szostak, J.W., T.L. Orr-Weaver, R.J. Rothstein and F.W. Sthal, 1983. The double-strand-break repair model for recombination. Cell, 33: 25-35.
CrossRef  |  PubMed  |  Direct Link  |  

Thomas, A.S., A. Mehta and D.A. Hughes, 2014. Gaucher disease: Haematological presentations and complications. Br. J. Haematol., 165: 427-440.
CrossRef  |  Direct Link  |  

Vitner, E.B. and A.H. Futerman, 2013. Neuronal forms of Gaucher disease. Sphingolipids Dis., 216: 405-419.
CrossRef  |  Direct Link  |  

Vitner, E.B., R. Salomon, T. Farfel-Becker, A. Meshcheriakova and M. Ali et al., 2014. RIPK3 as a potential therapeutic target for Gaucher’s disease. Nature Med., 20: 204-208.
CrossRef  |  Direct Link  |  

Vitner, E.B., T. Farfel-Becker, R. Eilam, I. Biton and A.H. Futerman, 2012. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher’s disease. Brain, 135: 1724-1735.
CrossRef  |  Direct Link  |  

WHO., 1991. Regulatory matters WHO drug information. World Health Organization, Geneva, Switzerland.

Wang, H.X., M. Li, C.M. Lee, S. Chakraborty, H.W. Kim, G. Bao and K.W. Leong, 2017. CRISPR/Cas9-based genome editing for disease modeling and therapy: Challenges and opportunities for nonviral delivery. Chem. Rev., 117: 9874-9906.
CrossRef  |  Direct Link  |  

Wang, S., J. Bates, X. Li, S. Schanz and D. Chandler-Militello et al., 2013. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell, 12: 252-264.
CrossRef  |  Direct Link  |  

Wei, H., S.J. Kim, Z. Zhang, P.C. Tsai, K.E. Wisniewski and A.B. Mukherjee, 2008. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet., 17: 469-477.
CrossRef  |  Direct Link  |  

Weinreb, N.J., P. Deegan, K.A. Kacena, P. Mistry, G.M. Pastores, P. Velentgas and S. vom Dahl, 2008. Life expectancy in Gaucher disease type 1. Am. J. Hematol., 83: 896-900.
CrossRef  |  Direct Link  |  

Westbroek, W., A.M. Gustafson and E. Sidransky, 2011. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med., 17: 485-493.
CrossRef  |  Direct Link  |  

Wiedenheft, B., S.H. Sternberg and J.A. Doudna, 2012. RNA-guided genetic silencing systems in bacteria and archaea. Nature, 482: 331-338.
CrossRef  |  Direct Link  |  

Wong, K., E. Sidransky, A. Verma, T. Mixon and G.D. Sandberg et al., 2004. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab., 82: 192-207.
CrossRef  |  Direct Link  |  

Wu, Y., D. Liang, Y. Wang, M. Bai and W. Tang et al., 2013. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell, 13: 659-662.
CrossRef  |  Direct Link  |  

Xie, F., L. Ye, J.C. Chang, A.I. Beyer, J. Wang, M.O. Muench and Y.W. Kan, 2014. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res., 24: 1526-1533.
CrossRef  |  Direct Link  |  

Yin, H., W. Xue, S. Chen, R.L. Bogorad and E. Benedetti et al., 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnol., 32: 551-553.
CrossRef  |  Direct Link  |  

Zhang, W., T. Wang, Z. Pei, D.S. Miller and X. Wu et al., 2005. Aggregated alphasynuclein activates microglia: A process leading to disease progression in Parkinson`s disease. FASEB J., 19: 533-542.
Direct Link  |